InflaRx (NASDAQ:IFRX) Now Covered by Analysts at Oppenheimer

Stock analysts at Oppenheimer assumed coverage on shares of InflaRx (NASDAQ:IFRX) in a report issued on Friday. The firm set an “outperform” rating and a $5.00 price target on the stock. Oppenheimer’s price objective would indicate a potential upside of 228.95% from the stock’s current price.

IFRX has been the subject of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a report on Friday, March 27th. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of InflaRx in a research report on Tuesday, December 30th. Guggenheim reissued a “buy” rating and issued a $14.00 price target on shares of InflaRx in a report on Tuesday. Finally, Raymond James Financial restated an “outperform” rating on shares of InflaRx in a research report on Wednesday, December 31st. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.50.

InflaRx Stock Performance

IFRX stock traded down $0.04 during midday trading on Friday, reaching $1.52. The stock had a trading volume of 81,980 shares, compared to its average volume of 590,079. The firm has a fifty day simple moving average of $1.01 and a two-hundred day simple moving average of $1.10. InflaRx has a 52-week low of $0.71 and a 52-week high of $1.94. The stock has a market cap of $109.88 million, a PE ratio of -2.03 and a beta of 1.49.

InflaRx (NASDAQ:IFRX) last released its earnings results on Friday, March 20th. The company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). The firm had revenue of ($0.04) million for the quarter, compared to analyst estimates of $0.03 million. On average, sell-side analysts predict that InflaRx will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC lifted its stake in shares of InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after buying an additional 7,616 shares in the last quarter. HRT Financial LP purchased a new stake in InflaRx during the 4th quarter valued at about $47,000. Concurrent Investment Advisors LLC raised its holdings in InflaRx by 56.9% in the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after acquiring an additional 19,200 shares during the last quarter. Insigneo Advisory Services LLC acquired a new stake in InflaRx in the 4th quarter valued at about $61,000. Finally, Quadrature Capital Ltd purchased a new position in InflaRx in the 4th quarter worth approximately $104,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.